BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Luc Biedermann  ¹     Alex Straumann  ²     Alfredo J. Lucendo  ³     Stephan Miehlke  ⁴     Michael Vieth  ⁵     Christoph Schlag     Cecilio Santander  ⁶     Constanza Ciriza de Los Rios  ⁷     Christoph Schmöcker  ⁸     Ahmed Madisch  ⁹     Petr Hruz  ¹⁰     Jamal Hayat  ¹¹     Ulrike von Arnim  ¹²     Arjan Bredenoord  ¹³     Stefan Schubert  ¹⁴     Ralph Mueller  ¹⁵     Roland Greinwald     Alain M. Schoepfer  ¹⁶     Stephen E. Attwood  ^17    
1 USZ Zürich, Zürich, Switzerland
² Swiss EoE Research Network, Olten, Switzerland
³ Hospital General de Tomelloso, Tomelloso, Spain
⁴ Internal Medicine Center Eppendorf, Hamburg, Germany
⁵ Friedrich-Alexander-University Erlangen-Nuremberg / Klinikum Bayreuth, Bayreuth, Germany
⁶ Hospital Universitario de la Princesa, Madrid, Spain
⁷ Hospital 12 de Octubre Dept. de Gastroenterologia, Madrid, Spain
⁸ Ruppiner Kliniken, Brandenburg Medical School, Neuruppin, Germany
⁹ CRH Clinic Hannover, Hannover, Germany
¹⁰ Clarunis, Basel, Switzerland
¹¹ St. George`s University Hospitals, London, United Kingdom
¹² Otto-Von Guericke University, Madgeburg, Germany
¹³ Amsterdam UMC, Amsterdam, Netherlands
¹⁴ Gastroenterologist in private practice, Berlin, Germany
¹⁵ Dr. Falk Pharma GmbH, Freiburg, Germany
¹⁶ University Hospital (CHUV), Lausanne, Switzerland
¹⁷ Durham University, North Tyneside, United Kingdom

Topic
Neurogastroenterology & Motility, Oesophagus

Session
Eosinophilic esophagitis and GORD

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)